Guidance has been published in the United Kingdom regarding a new European variations regulation that comes into effect on Jan. 1, 2010.
Guidance has been published in the United Kingdom regarding a new European variations regulation that comes into effect on Jan. 1, 2010. After consultation, UK health ministers have agreed that the new rules will be adopted for all variations to marketing authorizations, including those held only in the UK. Additionally, an amending fees regulation will be implemented in the UK to establish fees for the new types of work specified in the European Commission regulation. The information has been published on the UK's Medicines and Healthcare products Regulatory Agency (MHRA) website.
Commission
1234/2008,which will replace Regulations 1084/2003/EC and 1085/2003/EC, concerns variations to the terms of marketing authorizations that have been granted by the Commission in Centralized Procedures and by the National Licensing Authorities in Mutual Recognition, Decentralized or other harmonizing European Procedures.
According to MHRA, the Commission also intends to extend the scope of the regulation to include variations to "purely National" marketing authorizations. This exclusion will require further legislative changes and will probably not be implemented until 2011. UK health ministers, however, have agreed that the rules within the new regulation will be adopted for all variations to the terms of marketing authorizations, including those granted in “purely National” procedures.
The UK agency has also introduced, effective Jan. 1, 2010, new fee categories to cover grouped and bulk-group applications for multiple changes submitted as part of the same variation application and applications where the UK is the Reference Authority in a European work-sharing procedure.
Further details can be found in the MHRA's National marketing authorization variations Guidance.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.